D C Montefiori

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs
    Dennis Ellenberger
    Laboratory Branch, Centers for Disease Control and Prevention, Mail Stop G 19, Atlanta, GA 30333, USA
    Virology 340:21-32. 2005
  2. pmc Antibody-based HIV-1 vaccines: recent developments and future directions
    David Montefiori
    Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Med 4:e348. 2007
  3. pmc Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants
    Genevieve G Fouda
    Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    Retrovirology 10:3. 2013
  4. pmc Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Retrovirology 9:57. 2012
  5. pmc Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
  6. pmc LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays
    Britt Piehler
    LabKey Software, Seattle, Washington 98102, USA
    BMC Immunol 12:33. 2011
  7. pmc Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 75:10200-7. 2001
  8. pmc Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 72:1886-93. 1998
  9. pmc Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 74:254-63. 2000
  10. ncbi request reprint HIV vaccine development at Duke University Medical Center
    B F Haynes
    Department of Medicine, The Duke Center for Aids Research, Duke University Medical Center, Durham, NC 27710, USA
    Immunol Res 22:263-9. 2000

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs
    Dennis Ellenberger
    Laboratory Branch, Centers for Disease Control and Prevention, Mail Stop G 19, Atlanta, GA 30333, USA
    Virology 340:21-32. 2005
    ..They also suggest that expression of different forms of VLP has a significant effect on elicited cellular and humoral immunity...
  2. pmc Antibody-based HIV-1 vaccines: recent developments and future directions
    David Montefiori
    Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Med 4:e348. 2007
  3. pmc Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants
    Genevieve G Fouda
    Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    Retrovirology 10:3. 2013
    ....
  4. pmc Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Retrovirology 9:57. 2012
    ..We report here follow-up data on 5 such animals that received tenofovir for 8 to 14 years...
  5. pmc Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
    ..No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials...
  6. pmc LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays
    Britt Piehler
    LabKey Software, Seattle, Washington 98102, USA
    BMC Immunol 12:33. 2011
    ..Updating all instances of such a macro with new techniques can be unwieldy and introduce non-uniformity across multi-lab teams. Using Excel also poses challenges in centrally storing, sharing and associating raw data files and results...
  7. pmc Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 75:10200-7. 2001
    ....
  8. pmc Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 72:1886-93. 1998
    ..The results indicate that the ability of HIV-1 to be neutralized by sera from infected individuals depends on factors other than coreceptor usage...
  9. pmc Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 74:254-63. 2000
    ..6. In contrast to natural infection with SHIV-89.6, in which few animals make anti-V3 antibodies, C4-V3 peptides frequently induced anti-V3 antibodies that neutralized primary isolate SHIV strains...
  10. ncbi request reprint HIV vaccine development at Duke University Medical Center
    B F Haynes
    Department of Medicine, The Duke Center for Aids Research, Duke University Medical Center, Durham, NC 27710, USA
    Immunol Res 22:263-9. 2000
    ..This brief review summarizes ongoing work at the Duke University School of Medicine on HIV vaccine development...
  11. pmc Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 72:3427-31. 1998
    ..6, and SHIV-89.6P possess highly divergent, strain-specific neutralization epitopes. The results also provide insights into the requirements for raising neutralizing antibodies to primary isolates of HIV-1...
  12. pmc Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 75:5879-90. 2001
    ..The results demonstrate the feasibility of generating neutralizing antibodies and cellular immune responses that target an R5 primary HIV-1 isolate by vaccination in primates...
  13. ncbi request reprint Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 165:148-57. 2000
    ..w. CD45RA isoforms. Although the presence of the CCR5 Delta 32 mutation down-regulates HIV-1 infection of thymocytes, the functional CD45RA polymorphism does not alter the susceptibility of thymocytes to HIV-1 infection in vitro...
  14. pmc HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life
    N L Yates
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    Mucosal Immunol 6:692-703. 2013
    ..HIV-1 transmission frequently elicits mucosal HIV-1 envelope-specific IgA responses targeted to gp41 that have a short half-life...
  15. pmc epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals
    Haili Tang
    Department of Surgery, Box 2926, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9286-99. 2011
    ..We conclude that a region just below the base of the V3 loop, near the coreceptor binding domain of gp120, can be a target for autologous neutralization...
  16. pmc Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1
    Weihong Lai
    Department of Surgery, Duke University Medical Center, Box 2826, Durham, NC 27710 2926, USA
    Antimicrob Agents Chemother 52:128-36. 2008
    ..In summary, these results suggest that BA entry inhibitors can potently inhibit a broad spectrum of primary HIV-1 isolates by targeting the V3 loop of gp120...
  17. ncbi request reprint Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype
    Ranajit Pal
    Department of Cell Biology, Advanced BioScience Laboratories, Kensington, MD 20895, USA
    Virology 348:341-53. 2006
    ....
  18. ncbi request reprint Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
    Paul A Goepfert
    University of Alabama at Birmingham, 908 20th Street South, CCB 328, Birmingham, AL 35294, USA
    Vaccine 25:510-8. 2007
    ..Use of the recombinant proteins NefTat and gp120(W61D) formulated with the AS02A adjuvant system was previously shown to protect against AIDS in a rhesus macaque SHIV animal model system...
  19. pmc Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state
    Mikyung Kim
    Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, United States
    Vaccine 25:5102-14. 2007
    ..In addition, the anti-gp41 immune response was preferentially directed to the C-helical domain, away from the MPER. Future vaccine design needs to contend with the complexity of epitope display as well as immunodominance...
  20. pmc Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
    Yun Li
    Washington National Primate Center, University of Washington, 3000 Western Ave, Seattle, WA 98121, USA
    J Virol 82:638-51. 2008
    ..These results indicate the potential advantages for glycan modification in vaccine design, although the role of specific glycans requires further examination...
  21. doi request reprint Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope
    Susan W Barnett
    Novartis Vaccines and Diagnostics, Inc, 4560 Horton Street, Emeryville, California 94608, USA
    AIDS 22:339-48. 2008
    ..Worldwide, the majority of human immunodeficiency virus (HIV) infections occur by heterosexual transmission. Thus, the development of a vaccine that can prevent intravaginal HIV infection is an important goal of AIDS vaccine research...
  22. pmc Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization
    Jason Hammonds
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Virol 79:14804-14. 2005
    ....
  23. pmc Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain
    Ying Lian
    Chiron Corp, 4560 Horton St, 4 3, Emeryville, CA 94608
    J Virol 79:13338-49. 2005
    ..The pilot-scale production of the various TV1 DNA vaccine constructs and env proteins described here should provide an initial platform upon which to improve the immunogenicity of these subtype C HIV envelope vaccines...
  24. pmc Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate
    Ranajit Pal
    Advanced BioScience Laboratories, Kensington, MD 20895, USA
    J Med Primatol 34:226-36. 2005
    ....
  25. pmc Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
    Timothy Fouts
    Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 99:11842-7. 2002
    ....
  26. pmc Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
    Gerald Voss
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Virol 77:1049-58. 2003
    ..Furthermore, vaccination prevented the development of AIDS for more than 2.5 years. The combination of the regulatory proteins Nef and Tat together with the structural protein gp120 was required for vaccine efficacy...
  27. ncbi request reprint Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates
    Frederic M N Bertley
    Department of Medicine, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 172:3745-57. 2004
    ..Taken together, these data indicate that nasal vaccination with SHIV-DNA plus IL-2/Ig DNA and rMVA can provide significant protection from disease progression...
  28. ncbi request reprint DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime
    James M Smith
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 20:1335-47. 2004
    ..Based on the breadth of the T cell response and a trend toward higher titers of anti-Env Ab, we are moving forward with human trials of the noncodon-optimized VLP-expressing DNA...
  29. ncbi request reprint Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations
    Michael Vajdy
    Chiron Corporation, Vaccine Research, Emeryville, California 94608, USA
    AIDS Res Hum Retroviruses 20:1269-81. 2004
    ....
  30. pmc Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon respon
    Kristina Abel
    Center for Comparative Medicine, California National Primate Research Center, School of Veterinary Medicine, University of California Davis, California 95616, USA
    J Virol 77:3099-118. 2003
    ..Thus, innate as well as cellular anti-SIV immune responses appeared to contribute to the SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239...
  31. pmc Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques
    Brian J Rybarczyk
    Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Virol 78:3561-71. 2004
    ..This result suggests that diversification of the SIV env V1/V2 region is the result of a type-specific antibody response...
  32. pmc An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies
    Robert J Luallen
    ProSci Incorporated, 12170 Flint Place, Poway, CA 92064, USA
    J Virol 82:6447-57. 2008
    ....
  33. pmc DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory
    Mariana Manrique
    Department of Medicine, Children s Hospital Boston, Department of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS Res Hum Retroviruses 24:505-19. 2008
    ....
  34. pmc Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol
    Elizabeth Ramsburg
    Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Virol 78:3930-40. 2004
    ..The improved protection in MVA-boosted animals correlates with trends toward stronger prechallenge CD8(+)-T-cell responses to SHIV antigens and stronger postchallenge SHIV-neutralizing antibody production...
  35. pmc Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein
    Silvija I Staprans
    Emory Vaccine Center, 954 Gatewood Road, Atlanta, GA 30329, USA
    Proc Natl Acad Sci U S A 101:13026-31. 2004
    ..These data suggest suggest that candidate AIDS vaccines may not simply be either efficacious or neutral; they may also have the potential to be harmful...
  36. pmc Antiviral antibodies are necessary for control of simian immunodeficiency virus replication
    Christopher J Miller
    Center for Comparative Medicine, California National Primate Research Center, University of California, Davis, Davis, California 95616, USA
    J Virol 81:5024-35. 2007
    ..0001). These observations indicate that antiviral antibody responses are critical in maintaining effective control of SIV replication at early time points postinfection...
  37. ncbi request reprint Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV
    Koen K A Van Rompay
    California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA
    J Acquir Immune Defic Syndr 38:124-34. 2005
    ..The results of these investigations suggest that immunization of human infants with poxvirus-based HIV vaccine candidates may offer protection against early and late HIV infection through breastfeeding...
  38. ncbi request reprint Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration
    Zhi Song Qiao
    Laboratory of Immunobiology and Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 280:23138-46. 2005
    ..Moreover, this engineered mini-Env protein should facilitate three-dimensional structural studies of the prefusion e-gp41 and serve to guide future attempts at pharmacologic and immunologic intervention of HIV-1...
  39. pmc Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins
    Gillis R Otten
    Chiron Corporation, 4560 Horton St, Mail Stop 4 3, Emeryville, California 94608, USA
    J Virol 79:8189-200. 2005
    ....
  40. ncbi request reprint Alphavirus replicon particles as candidate HIV vaccines
    Nancy L Davis
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill 27599, USA
    IUBMB Life 53:209-11. 2002
    ..A GMP lot of this vaccine has been manufactured and tested for a phase I trial in the first months of 2002...